

CP/CB

PPUBLIC DOCUMENT
(Level 1)

English/Chinese

PA/PH/Exp.CEP/T(06)13, 1R

Strasbourg, July 2004

Certification of suitability of Monograph of the European Pharmacopoeia
欧洲药典适应性证书

Certificate of suitability for sterile active substances
无菌活性物质的适应性证书

| | | |
|--|---------------------------|---------------|
| Publication on the website and implementation | PA/PH/Exp.CEP/T(06)13 | 15 April 2006 |
| Corrected version: publication on the website and implementation | PA/PH/Exp.CEP/T(06)13, 1R | August 2006 |
| 网站公布和执行 | PA/PH/Exp.CEP/T(06)13 | 2006年4月15日 |
| 更正版: 网站公布和执行 | PA/PH/Exp.CEP/T(06)13, 1R | 2006年8月 |

Certificate of suitability for sterile active substances 无菌活性物质的适应性证书

It is possible to apply for a certificate of suitability for a sterile active ingredient. The conditions and procedures for this option have been defined and are described below:

可以申请无菌活性成份的欧洲药典适用性证书。申报的前提和具体要求如下:

- The substance shall be sterile and shall comply with the test for sterility 2.6.1 described in the European Pharmacopoeia.
- 必须无菌，并符合EP2.6.1无菌检验要求
- The sterilization process shall be described in detail in the application, together with full data on the validation of the sterilization method.
- 申报文件必须详细描述灭菌工艺过程，必须同时提供该灭菌方法的完整验证资料
- The company shall refer to suitable GMP rules. The *Good Manufacturing Practice for Active Pharmaceutical Ingredients* (ICHQ7A) only applies to the manufacture of sterile active pharmaceutical ingredients (APIs) up to the point immediately prior to the APIs being rendered sterile. The sterilisation and aseptic processing of sterile APIs are not covered by this guideline and shall be performed in accordance with GMP for medicinal products (Commission Directive 2003/94/EC of 8 October 2003, laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and investigational medicinal products for human use, or equivalent). When a company applies for a certificate of suitability for a sterile active ingredient, declarations referring to appropriate GMP covering the sterilisation steps and subsequent aseptic handling are to be provided. Depending on the legislation in force in the country in which the manufacturer is located these steps may be subject to the holding of a manufacturing authorization or establishment license, and/or subject to regular inspections by a regulatory authority for medicinal products.
- 公司必须符合合适的GMP规定。活性成份生产质量管理规范（ICHQ7A）只适用于无菌活性药用成份无菌生产之前的生产过程。该指南不适用于无菌API的灭菌和无菌生产，此时必须执行药品GMP（委员会法规Directive 2003/94/EC，2003年10月8日生效，是人用药品和开发人用药品GMP指南和基本原则）。如果一个公司申请无菌活性成份欧洲药典适用性证书，必须提供在灭菌过程和相关无菌操作中符合GMP的声明。根据申请人所处国家立法情况不同，这些灭菌或无菌过程可能会被要求有生产许可证或企业证，或定期接受药政部门的检查。
- Unless evidence is provided that the manufacturer is subject to routine inspections by a

regulatory authority, the manufacturing site(s) involved in the sterilization and aseptic handling of the sterile active substance will be inspected within the EDQM inspection program, (fee for inspection will also apply).

- 如果没有证据证明生产厂定期接受法规部门检查，EDQM将按其检查程序对无菌活性成份灭菌和无菌生产和场所进行检查，（同时收取检查费用）。
- If both sterile and non-sterile substances are produced, separate dossier shall be submitted and separate CEPs will be granted.
- 如果同时生产无菌和非无菌级别，必须分别报送文件，CEP证书将分别签发。
- Additional fee for assessment of the sterilization data will be required (3000 Euros).
- 无菌资料评审另收取3000欧元费用。

When granted, the CEP will include the relevant subtitle (“sterile”), it will specify the sterilisation method used and will refer to the test for sterility. It will also be mentioned that the sterilization process has been assessed and approved.

一旦签发CEP证书，证书上将有相应小标题（“无菌”），同时还会规定灭菌方法和无菌检验方法。同时还会说明已经对灭菌工艺进行了评审，并予以接受。

It should be noted that sterilisation of the active ingredient is generally regarded by the licensing authorities as part of finished product manufacture. Therefore data on the sterilization process of the active substance (including validation data) should be submitted to the Marketing Authorisation applicant/holder for inclusion in the dossier submitted for the finished product and approval by the national licensing authority(ies).

应注意的是：签发销售许可证的当局将活性成份无菌生产部份视为成品制剂生产的一部分。因此，必须向制剂销售许可证申请人/持有人的申报所有活性成分的无菌工艺资料（包括验证数据），从而使制剂MA申请人/持有人将该资料包括在制剂申报资料，供各国药政部门审批。

For CEPs which have already been granted with the subtitle “sterile”, and for which the validation of the sterilization process has not yet been assessed, the data have to be submitted to EDQM at the latest at the renewal of the CEP, or through a revision. The dossier will be treated as described above and the additional fee will also be applied. Failure to comply with these requirements will lead to the withdrawal of the information related to sterility aspects from the CEP.

已经签发的“无菌” CEP证书， EDQM没有评审过生产厂的无菌工艺验证资料时， 至少应在证书更新时向EDQM申报， 或以修订方式进行申报。 申报文件将按上述程序受理， 同时申报人必须缴纳上述费用。 否则， CEP证书将取消有关无菌的内容。